AJArne Janssens

Arne Janssens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arne Janssens has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of potential bias mechanisms in the analysis of large electronic medical record datasets

    by Arne Janssens, Jonas Crèvecoeur, Pieter J. K. Libin, Gijs Van Pottelbergh, Bert Vaes, Thomas Neyens

    Electronic medical records aid general practitioners in the follow-up of their patients. The vast amounts of patient data that are being collected through such electronic medical records offer opportunities to use them for other purposes such as epidemiological and (pre)clinical research. But the use of electronic medical record data for research purposes raises concerns about potential biases, since these data are typically not collected within a study design specifically developed to address a predefined research question, which may instead emerge during or after data collection. In addition, data collection practices and reporting behaviours can vary between general practitioners, while patients themselves differ in their likelihood of seeking care or reporting symptoms. Although a large patient population may mitigate some of these random variations through the law of large numbers, systematic biases related to the non-randomized sample of the participating practices and heterogeneity in patient characteristics may persist. If not appropriately accounted for, these sources of heterogeneity and potential bias can lead to different or potentially conflicting research findings. Using a large electronic medical records dataset from Flanders, Belgium, we assess how simple statistical approaches, such as adding practice-level random effects and changing the analytical entity, can help identify potential bias mechanisms and assess the sensitivity of estimated associations to them.

  • Open Access

    A lifecycle-aware framework for assessing data quality across sequential ETL transformations: application to the INTEGO-II primary care database (Preprint)

    by Jens Declerck, Sonia Priou, Ahmed Medhat Zayed, Arne Janssens, Maarten Caspers, Bert Vaes, Robert Vander Stichele, Dipak Kalra, Pascal Coorevits

    BACKGROUND Routinely collected EHR data are increasingly repurposed for secondary use. As data move through multi-stage pipelines, data quality losses can be introduced at each transformation step. Yet most assessment approaches treat data quality as a static, post-hoc property of a final dataset, making transformation induced losses invisible. Emerging regulatory frameworks demand transparency and traceability across the full data lifecycle but provide limited operational guidance on how to achieve this. OBJECTIVE To introduce a lifecycle framework for assessing data quality across sequential ETL transformations and validate it using the Intego-II database. METHODS The framework comprised two components: information loss and selection bias. It was applied to Intego-II database by comparing three dataset representations within ETL Stage 2: pseudonymised source data, transformed data, and standardised data. Four indicators were evaluated across the condition, procedure, and drug exposure domains: patient coverage, domain coverage, temporal coverage, and mapping coverage. TPQAs evaluated selection bias using Cohen’s d and standardised mean differences. RESULTS Patient attrition of 31,6% (1,421,150 to 971,762) arose from SSN-based deduplication of legacy EHR records and eligibility-driven exclusion. ICD-10 to SNOMED CT mapping achieved 58,3% coverage, attributable to a decimal separator inconsistency affecting 3,871 codes and approximately 326,800 condition records (1,7%). Drug concept granularity was compressed by 99,9% due to three co-occurring failures: non-standard source codes, incomplete national mapping coverage, and structural ATC-to-RxNorm vocabulary gaps. TPQA-1 showed eligibility-driven attrition was demographically neutral (Cohen’s d = -0,003; SMD = 0,031). TPQA-2 identified vocabulary-driven drug domain loss disproportionately affecting older patients (Cohen’s d = -0,49). CONCLUSIONS Sequential ETL processing introduces heterogeneous, mechanism-specific data quality losses invisible to post-hoc assessment. The framework is reproducible, generalisable, and supports the transparency and traceability requirements of the European Health Data Space and EU AI Act.

  • Open Access

    Spatial inequalities in cardiovascular health: a cross-sectional study with small-area health insurance claims and individual-level primary care data in Belgium

    by Arne Janssens, Sumbul Hashmi, Anne-Laure Budts, Lorenz Van der Linden, Wies Kestens, Spencer Marcinko, Chiel Hex, Thomas Neyens, Ellie D’HOndt, Caroline Van Cauwelaert, et al.

    Aims: Atherosclerotic cardiovascular disease (ASCVD) continues to pose a growing burden driven by aging, comorbidities, and socioeconomic vulnerability. Yet, the regional distribution of these disparities remains poorly characterized, partly because no single dataset provides comprehensive ASCVD surveillance data. To address this gap, we combined insights from small-area health insurance claims and individual-level primary care data to assess how socioeconomic vulnerability relates to ASCVD indicators across regional contexts in Belgium. Methods: We conducted a cross-sectional study using two complementary data sources: (i) small-area ASCVD indicators from a nationwide health insurance organization and (ii) individual-level clinical diagnoses from a general practice (GP) registry in Flanders. A multidimensional small-area socioeconomic vulnerability index was constructed using established methodology. Associations were examined using Spearman correlation, Mann-Whitney U tests, bootstrapping, and hierarchical logistic regression models. Results: Both small-area health insurance claims data and small-area predictions derived from individual-level GP registry data revealed regional disparities in ASCVD prevalence that overlapped with patterns of socioeconomic vulnerability. Socioeconomic vulnerability was positively correlated with ASCVD prevalence at both small-area and individual levels. In the claims dataset, the median ASCVD prevalence was 1.57 times higher (95% CI: 1.46–1.65) in high-vulnerability areas compared with low-vulnerability areas. In the GP registry, overall ASCVD prevalence was 6.46%, with marked disparities by age, sex, socioeconomic status, and lipid-lowering medication. Increased compensation, a proxy for individual-level socioeconomic vulnerability, was associated with higher ASCVD prevalence, particularly among individuals not receiving lipid-lowering therapy. Small-area risk estimates of increased compensation derived from the GP registry showed moderate agreement with the multidimensional vulnerability index. An accompanying geoportal visualizes small-area data, enabling stakeholders to identify high-vulnerability areas and support targeted public health interventions. Conclusion: Combining small-area health insurance claims with individual-level primary care data provides a more comprehensive framework for cardiovascular health surveillance, revealing socioeconomic disparities that are not fully captured by either dataset alone. The agreement between the findings from these data sources strengthens confidence in the observed spatial patterns and highlights regional inequalities in indicators of ASCVD prevalence across Belgium, underscoring the value of integrated data approaches for public health monitoring and the need for localized public health interventions addressing both area-level and individual-level social determinants of health.

  • Temporal trends in antibiotic prescribing and serious and nonserious infections in children presenting to general practice: a registry-based longitudinal cohort study of 162 507 individuals

    by Ruben Burvenich, Sien De Boodt, Lien Lowie, Arne Janssens, Simon Gabriël Beerten, Bert Vaes, Jaan Toelen, Jan Yvan Verbakel

    Background: It is crucial to understand the trends in paediatric antibiotic prescribing and serious and nonserious infections to improve antibiotic prescribing practices for children in ambulatory care.Objectives: Assessing trends in paediatric antibiotic prescribing and infection incidence in general practice from 2002 to 2022.Methods: In this retrospective cohort study using INTEGO network data from 162 507 patients in Flanders (Belgium), we calculated antibiotic prescribing rates and proportions alongside incidence rates of serious and nonserious infections, stratified by age (0–1, 2–6, 7–12 years) and municipality. We performed autoregressive moving average time-series analyses and seasonality analyses.Results: From 2002 to 2022, antibiotic prescribing rate decreased significantly: 584/1000 person-years (PY) (95% CI 571–597) to 484/1000PY (95% CI 478–491); so did antibiotic overall prescribing proportion: 46.3% (95% CI 45.1–47.6) to 23.3% (95% CI 22.9–23.7) (59.3% amoxicillin and 17.8% broad spectrum). Prescribing proportions dropped significantly for nonserious (45.6% to 20.9%) and increased for serious infections (64.1% to 69.8%). Proportions significantly dropped for acute suppurative otitis media (74.7% to 64.1%), upper respiratory tract infections (44.9% to 16.6%), bronchitis/bronchiolitis (73.6% to 44.1%) and acute tonsillopharyngitis (59.5% to 21.7%), while significantly increasing for pneumonia (65.2% to 80.2%). Nonserious and serious infection incidence rates increased from 785/1000PY and 34.2/1000PY to 1223/1000PY and 64.1/1000PY, respectively. Blood and CRP testing proportions increased significantly.Conclusions: Antibiotic prescribing in general practice for children declined from 2002 to 2022. Further targeted antibiotic stewardship initiatives are needed to reduce the use of broad-spectrum antibiotics and antibiotic prescribing for conditions such as otitis media and bronchitis/bronchiolitis.


  • Open Access

    Model-based disease mapping using primary care registry data

    by Arne Janssens, Bert Vaes, Gijs Van Pottelbergh, Pieter J.K. Libin, Thomas Neyens


  • A longitudinal transition imputation model for categorical data applied to a large registry dataset

    by Pavlos Mamouris, Vahid Nassiri, Geert Verbeke, Arne Janssens, Bert Vaes, Geert Molenberghs

    Imputation of longitudinal categorical covariates with several waves and many predictors is cumbersome in terms of implausible transitions, colinearity, and overfitting. We designed a simulation study with data obtained from a general practitioners' morbidity registry in Belgium for three waves, with smoking as the longitudinal covariate of interest. We set varying proportions of data on smoking to missing completely at random and missing not at random with proportions of missingness equal to 10%, 30%, 50%, and 70%. This study proposed a 3‐stage approach that allows flexibility when imputing time‐dependent categorical covariates. First, multiple imputation using fully conditional specification or multiple imputation for the predictor variables was deployed using the wide format such that previous and future information of the same patient was utilized. Second, a joint Markov transition model for initial, forward, backward, and intermittent probabilities was developed for each imputed dataset. Finally, this transition model was used for imputation. We compared the performance of this methodology with an analyses of the complete data and with listwise deletion in terms of bias and root mean square error. Next, we applied this methodology in a clinical case for years 2017 to 2021, where we estimated the effect of several covariates on the pneumococcal vaccination. This methodological framework ensures that the plausibility of transitions is preserved, overfitting and colinearity issues are resolved, and confounders can be utilized. Finally, a companion R package was developed to enable the replication and easy application of this methodology.


  • Open Access

    Pneumococcal vaccination coverage and adherence to recommended dosing schedules in adults: a repeated cross-sectional study of the INTEGO morbidity registry

    by Arne Janssens, Bert Vaes, Chloé Abels, Jonas Crèvecoeur, Pavlos Mamouris, Barbara Merckx, Pieter Libin, Gijs Van Pottelbergh, Thomas Neyens

    Background: Since 2014, Belgium’s Superior Health Council has recommended pneumococcal vaccination for adults aged 19–85 years at increased risk for pneumococcal diseases with a specific vaccine administration sequence and timing. Currently, Belgium has no publicly funded adult pneumococcal vaccination program. This study investigated the seasonal pneumococcal vaccination trends, evolution of vaccination coverage and adherence to the 2014 recommendations. Methods: INTEGO is a general practice morbidity registry in Flanders (Belgium) that represents 102 general practice centres and comprised over 300.000 patients in 2021. A repeated cross-sectional study was performed for the period between 2017 and 2021. Using adjusted odds ratios computed via multiple logistic regression, the association between an individual’s characteristics (gender, age, comorbidities, influenza vaccination status and socioeconomic status) and schedule-adherent pneumococcal vaccination status was assessed. Results: Pneumococcal vaccination coincided with seasonal flu vaccination. The vaccination coverage in the population at risk decreased from 21% in 2017 to 18.2% in 2018 and then started to increase to 23.6% in 2021. Coverage in 2021 was highest for high-risk adults (33.8%) followed by 50- to 85-year-olds with comorbidities (25.5%) and healthy 65- to 85-year-olds (18.7%). In 2021, 56.3% of the high-risk adults, 74.6% of the 50+ with comorbidities persons, and 74% of the 65+ healthy persons had an adherent vaccination schedule. Persons with a lower socioeconomic status had an adjusted odds ratio of 0.92 (95% Confidence Interval (CI) 0.87–0.97) for primary vaccination, 0.67 (95% CI 0.60–0.75) for adherence to the recommended second vaccination if the 13-valent pneumococcal conjugate vaccine was administered first and 0.86 (95% CI 0.76–0.97) if the 23-valent pneumococcal polysaccharide vaccine was administered first. Conclusion: Pneumococcal vaccine coverage is slowly increasing in Flanders, displaying seasonal peaks in sync with influenza vaccination campaigns. However, with less than one-fourth of the target population vaccinated, less than 60% high-risk and approximately 74% of 50 + with comorbidities and 65+ healthy persons with an adherent schedule, there is still much room for improvement. Furthermore, adults with poor socioeconomic status had lower odds of primary vaccination and schedule adherence, demonstrating the need for a publicly funded program in Belgium to ensure equitable access.


  • Open Access

    Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential

    by Steffie K Naber, Suman Kundu, Karen M Kuntz, W David Dotson, Marc S Williams, Ann G Zauber, Ned Calonge, Doris T Zallen, Theodore G Ganiats, Elizabeth M Webber, et al.

    Background: Although uniform colonoscopy screening reduces colorectal cancer (CRC) mortality, risk-based screening may be more efficient. We investigated whether CRC screening based on polygenic risk is a cost-effective alternative to current uniform screening, and if not, under what conditions it would be.Methods: The MISCAN-Colon model was used to simulate a hypothetical cohort of US 40-year-olds. Uniform screening was modeled as colonoscopy screening at ages 50, 60, and 70 years. For risk-stratified screening, individuals underwent polygenic testing with current and potential future discriminatory performance (area under the receiver-operating curve [AUC] of 0.60 and 0.65–0.80, respectively). Polygenic testing results were used to create risk groups, for which colonoscopy screening was optimized by varying the start age (40–60 years), end age (70–85 years), and interval (1–20 years).Results: With current discriminatory performance, optimal screening ranged from once-only colonoscopy at age 60 years for the lowest-risk group to six colonoscopies at ages 40–80 years for the highest-risk group. While maintaining the same health benefits, risk-stratified screening increased costs by $59 per person. Risk-stratified screening could become cost-effective if the AUC value would increase beyond 0.65, the price per polygenic test would drop to less than $141, or risk-stratified screening would lead to a 5% increase in screening participation.Conclusions: Currently, CRC screening based on polygenic risk is unlikely to be cost-effective compared with uniform screening. This is expected to change with a greater than 0.05 increase in AUC value, a greater than 30% reduction in polygenic testing costs, or a greater than 5% increase in adherence with screening.